000			02043 a2200601 4500
005			20250515020631.0
264		0	_c20060425
008			200604s 0 0 eng d
022			_a0027-8424
024	7		_a10.1073/pnas.0508123103 _2doi
040			_aNLM _beng _cNLM
100	1		_aLazar, Greg A
245	0	0	_aEngineered antibody Fc variants with enhanced effector function. _h[electronic resource]
260			_bProceedings of the National Academy of Sciences of the United States of America _cMar 2006
300			_a4005-10 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAlemtuzumab
650	0	4	_aAnimals
650	0	4	_aAntibodies, Monoclonal _xgenetics
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntibodies, Neoplasm _xgenetics
650	0	4	_aAntibody Affinity
650	0	4	_aAntibody Specificity
650	0	4	_aAntibody-Dependent Cell Cytotoxicity
650	0	4	_aAntineoplastic Agents _xmetabolism
650	0	4	_aB-Lymphocytes _ximmunology
650	0	4	_aComplement System Proteins _xmetabolism
650	0	4	_aCytotoxicity, Immunologic
650	0	4	_aGenetic Variation
650	0	4	_aHumans
650	0	4	_aImmunoglobulin Fc Fragments _xgenetics
650	0	4	_aIn Vitro Techniques
650	0	4	_aLymphocyte Depletion
650	0	4	_aMacaca fascicularis
650	0	4	_aProtein Engineering
650	0	4	_aReceptors, IgG _xmetabolism
650	0	4	_aTrastuzumab
700	1		_aDang, Wei
700	1		_aKarki, Sher
700	1		_aVafa, Omid
700	1		_aPeng, Judy S
700	1		_aHyun, Linus
700	1		_aChan, Cheryl
700	1		_aChung, Helen S
700	1		_aEivazi, Araz
700	1		_aYoder, Sean C
700	1		_aVielmetter, Jost
700	1		_aCarmichael, David F
700	1		_aHayes, Robert J
700	1		_aDahiyat, Bassil I
773	0		_tProceedings of the National Academy of Sciences of the United States of America _gvol. 103 _gno. 11 _gp. 4005-10
856	4	0	_uhttps://doi.org/10.1073/pnas.0508123103 _zAvailable from publisher's website
999			_c16146310 _d16146310